Abstract FR428: Cardiovascular Effects of Chronic GLP-1-GIP and GLP-1-GIP-Glucagon Agonist Treatments on High-Fat Diet Fed 3xTg-AD Mice
Hypertension · 2026-10 · 83 (Suppl_1)
DOI: 10.1161/hyp.83.suppl_1.fr428 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hypertension, 2026-10. Verfasst von Robert Speth und 3 weiteren Autor:innen.
Abstract (Originalsprache)
The success of GLP-1 receptor agonists and newer multi-agonist incretin drugs for obesity and diabetes has generated significant interest in their broader physiological actions, including effects on cardiovascular function. This is especially relevant for Alzheimer’s disease (AD), where obesity, diabetes, and cardiovascular dysfunction commonly co-occur and may affect disease progression and treatment response. Here, we assess the cardiovascular effects of the dual GLP-1-GIP agonist tirzepatide (TIRZEP) and the triple GLP-1-GIP-glucagon agonist retatrutide (RETA) in male and female 3xTg-AD mice maintained on a high fat diet. This allows us to evaluate these incretin-based therapies in a model that incorporates both AD pathology and metabolic comorbidity. Beginning at 3-4 months of age, mice were fed a high-fat diet (HFD) for 10 weeks, then received subcutaneous injections of PBS vehicle, TIRZEP (20 nmol/kg), or RETA (20 nmol/kg) three times weekly for 3 months. Wild-type and 3xTg-AD control mice received low-fat diet and vehicle injections. Outcomes included body weight, food intake, glucose tolerance, systolic blood pressure (SBP), and heart rate (HR). As expected, drug treatment significantly reduced weight gain and adiposity, while improving glucose tolerance. Several effects were more pronounced in females, potentially in part because HFD produced greater baseline metabolic impairment in 3xTg-AD females than males, including increased weight gain, adiposity, and glucose intolerance. SBP was substantially lower in female mice (104 mm Hg) compared to males overall (114 mm Hg) and across all treatment groups; this finding is in agreement with previously reported sex differences in blood pressure in other mouse strains and species, including humans. HFD did not result in hypertension in either males or females. Tirzepatide (-12.6 mm Hg) and retatrutide (-13.7 mm Hg) reduced SBP in male 3xTg-AD mice but showed a smaller trend toward reducing SBP in female 3xTg-AD mice (-8.6 and -6.8 mmHg respectively). Heart rate was significantly lower in female mice (720 BPM) compared to males (766 BPM), while HFD had no effect. Only TIRZEP reduced HR and only in males (p
Zitieren
APA
Speth, R., Martin, K., Parmar, M., & Robison, L. (2026). Abstract FR428: Cardiovascular Effects of Chronic GLP-1-GIP and GLP-1-GIP-Glucagon Agonist Treatments on High-Fat Diet Fed 3xTg-AD Mice. Hypertension, 83(Suppl_1). https://doi.org/10.1161/hyp.83.suppl_1.fr428
Vancouver
Speth R, Martin K, Parmar M, Robison L. Abstract FR428: Cardiovascular Effects of Chronic GLP-1-GIP and GLP-1-GIP-Glucagon Agonist Treatments on High-Fat Diet Fed 3xTg-AD Mice. Hypertension. 2026;83(Suppl_1). doi:10.1161/hyp.83.suppl_1.fr428
BibTeX
@article{Speth2026,
author = {Speth, Robert and Martin, Kaitlin and Parmar, Mayur and Robison, Lisa},
title = {Abstract FR428: Cardiovascular Effects of Chronic GLP-1-GIP and GLP-1-GIP-Glucagon Agonist Treatments on High-Fat Diet Fed 3xTg-AD Mice},
journal = {Hypertension},
year = {2026},
volume = {83},
number = {Suppl_1},
doi = {10.1161/hyp.83.suppl_1.fr428}
}
EUVIMED